Back

The role of TAK1 inhibition in doxorubicin-induced cardiotoxicity: an in vitro study

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Cardio-oncology and therapy Cancer Biology and Treatment ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Associate Professor Bertha Polegato

Faculty of Medicine of Botucatu, UNESP, Botucatu (Brazil)

3 More presentations in this session

Presentation thumbnail
NLRP3/IL-1 pathway was reduced by semaglutide and dapagliflozin in association therapy under exposure to anthracyclines in hyperglycemic conditions
Doctor N. Maurea (Naples, IT)
Abstract Slides Video
Presentation thumbnail
Age- and sex-specific association between clonal hematopoiesis of indeterminate potential and pulmonary hypertension
Doctor G. Sun (Guangzhou, CN)
Abstract Slides Video
Presentation thumbnail
Variability in echocardiographic surveillance for cardiotoxicity in HER2+ versus HER2- breast cancer: a SEER-medicare analysis
Associate Professor J. Strom (Boston, US)
Abstract Slides Video

Access the full session

Session thumbnail
Cardio-oncology and therapy

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Silencing of microRNA-106b-5p prevents doxorubicin-mediated cardiotoxicity through modulation of the PR55/YY1/sST2 signaling axis
thumbnail
Congress Presentation
Chalcone-enriched fraction protects against chemotherapy-induced cardiotoxicity by restoring mitochondrial function and reducing oxidative stress
thumbnail
Congress Presentation
Deciphering doxorubicin-induced cardiotoxicity:insights at single-cell resolution

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources